Key regulatory points for Epitalon Australia compliance: Epitalon is not approved by the Therapeutic Goods Administration (TGA) as a registered medicine for human or veterinary use It is classified strictly for laboratory and research purposes, not for human consumption Supply, import, and handling of research peptides fall under Australian regulatory oversight, and institutions should confirm current scheduling status directly through TGA resources before procurement Any research involving human subjects must comply with Research Ethics Committee approval and applicable Good Clinical Practice standards Marketing or supplying Epitalon with therapeutic claims, or implying suitability for human treatment, falls outside permitted research-use classifications Researchers and institutions should treat Epitalon strictly as a laboratory reagent, ensuring internal documentation, handling protocols, and communications consistently reflect its research-only status
Their combined effect, however, has not been clinically studied
Despite their therapeutic potential, conventional metal-based nanomaterials (e.g., silver, gold, titanium dioxide) are considered environmentally unsustainable due to their persistence, poor biodegradability, and potential toxicity [114]
It supports collagen production, tissue repair, and healthy aging from within
This early cosmetic enhancement proves encouraging but shouldn't be mistaken for actual dark circle reduction requiring substantially longer peptide treatment duration as described in SeekPeptides timeline guides
Please note that the folder also contains scripts that can be used to conveniently reproduce the analysis in the manuscript.
